cyprotex
the ADME Tox specialists
welcome to cyprotex

News

February 25, 2009 - Directorate Changes

Cyprotex PLC (AIM: CRX) today announces the resignation of David Evans as a Non-executive Director of the Company with immediate effect and the appointment of John Dootson as Chief Financial Officer effective from 2 March 2009.

Commenting on the directorate changes, Steve Harris, Chairman of Cyprotex said: "David has made a significant contribution to the Company as a Non-executive Director and the Board would like to thank him for his contribution to the Company and wish him well with his future endeavours.

The Company is very pleased to appoint John Dootson as Chief Financial Officer. John has been associated with the Company for over four years as a consultant Financial Controller and therefore has intimate knowledge of the Company's business and finances. He brings to the Company wide ranging financial expertise gained in both industry and private practice."

Notes for Editors:

John Dootson, aged 47, has 25 years experience in both professional practice and in industry. Trained with Tenon and Ernst & Young, John has extensive managerial experience in major accounting practices and has worked on a wide range of projects including London Stock Exchange flotations and circulars, corporate governance, company acquisitions and disposals and specialist advice to growing SMEs. John has also worked in a number of roles in Industry at Financial Controller and Director level, including seven years within the senior head office finance team of BTP plc, a former FTSE250 specialty chemical manufacturer with over 50 sites worldwide prior to its sale to Clariant AG for 1.1bn GBP.

John is a Fellow of the Institute of Chartered Accountants in England and Wales and for the last four years he has assisted Cyprotex in a management consultative role that has included all aspects of finance and reporting.

The following information relating to Mr. Dootson is provided in compliance with the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies:

Full name and age: John Kevin Dootson, age 47.

Present directorships: Downham Mayer Clarke Limited

Directorships during the past five years: Downham Mayer Clarke Limited

Mr. Dootson has not been a director of any company which has been wound up or placed in administration or receivership.

Mr. Dootson holds no shares in the Company.


There are no further disclosures to be made in respect of Mr. Dootson under the provisions of Rule 17, Schedule Two, paragraph (g) of the AIM Rules for Companies.

For further information:
Cyprotex PLC

Tony Baxter, CEO
Mark Warburton, Company Secretary
Tel: +44 (0)1625 505 100


Noble & Company Limited

John Llewellyn-Lloyd
Sam Reynolds
Tel: +44 (0)20 7763 2200

view all the latest news +
2013 archive +
2012 archive +
2011 archive +
2010 archive +
2009 archive +
2008 archive +
2007 archive +
2006 archive +
2005 archive +
2004 archive +
2003 archive +
2002 archive +
contact

Contact us for more information on Cyprotex Discovery, including our extensive range of ADMET/PK services
and pricing.

contact
careerscontactlegalprivacy
This website was last updated
on 16th April 2014
This website is intended to assist investors, industry participants, customers and employees to understand Cyprotex’s global operations and ambitions.
Certain information and detail is disclosed in the interest of compliance of AIM Rule 26.